Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Andros Pharmaceuticals Co's total inventories for the quarter that ended in Dec. 2025 was NT$1.53 Mil. Andros Pharmaceuticals Co's average total inventories from the quarter that ended in Jun. 2025 to the quarter that ended in Dec. 2025 was NT$1.21 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Andros Pharmaceuticals Co's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was NT$5.94.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Andros Pharmaceuticals Co's Days Inventory for the
six
months ended in Dec. 2025 was 60.06.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Andros Pharmaceuticals Co's Inventory Turnover for the quarter that ended in Dec. 2025 was 3.04.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Andros Pharmaceuticals Co's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.22.
Andros Pharmaceuticals Co (ROCO:6917) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Andros Pharmaceuticals Co's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Andros Pharmaceuticals Co's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Andros Pharmaceuticals Co Total Inventories Related Terms
Andros Pharmaceuticals Co Total Inventories Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Andros Pharmaceuticals Co Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
What does a Total Inventories of NT$1.53 Mil mean?
Andros Pharmaceuticals Co (ROCO:6917) has a Total Inventories of NT$1.53 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Andros Pharmaceuticals Co and its competitors.
Is Andros Pharmaceuticals Co's Total Inventories too high?
Andros Pharmaceuticals Co's current Total Inventories is NT$1.53 Mil. Overall, Andros Pharmaceuticals Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Andros Pharmaceuticals Co's Total Inventories compare to VRTX and REGN?
Andros Pharmaceuticals Co's Total Inventories of NT$1.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Andros Pharmaceuticals Co and its competitors. Andros Pharmaceuticals Co's current Total Inventories is NT$1.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Andros Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Andros Pharmaceuticals Co (ROCO:6917) is currently considered Possible Value Trap. The stock's GF Value™ is NT$165.02, compared to a current price of NT$34.50 — trading 79.1% below its estimated fair value. The current Total Inventories is NT$1.53 Mil. Andros Pharmaceuticals Co's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Andros Pharmaceuticals Co (ROCO:6917), the current Total Inventories is NT$1.53 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Andros Pharmaceuticals Co (ROCO:6917) Overvalued in 2026?
Based on GuruFocus' analysis, Andros Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$34.50 is trading 79.1% below its estimated GF Value™ of NT$165.02.
GuruFocus considers Andros Pharmaceuticals Co to be Possible Value Trap.
Key valuation signals for ROCO:6917:
Total Inventories: NT$1.53 Mil
GF Value™: NT$165.02 vs. price of NT$34.50 (79.1% below fair value)
No single metric tells the full story. See the ROCO:6917 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).
41GF Score
Get the complete analysis for ROCO:6917
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6917 has been successfully added to your 
